Press release

Menlo Park, CA

Orca Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

MENLO PARK, CA, January 6, 2021 – Orca Bio, a clinical-stage biotechnology company developing high-precision cell therapies for patients with blood diseases, today announced that Ivan Dimov, PhD, Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference. The presentation will be held virtually on Monday, January 11, 2021, at 1:55 PM PT (4:55 PM ET), immediately followed by a Q&A session.

Management will be available for meetings during the week of the conference.

About Orca Bio

Orca Bio is a late-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders. Our investigational therapies are designed to deliver better survival rates with dramatically fewer risks than the standard of care. At Orca Bio, we hope to not only replace patients' blood and immune systems with healthy ones, but restore their quality of life. For more information, visit and follow Orca Bio on Twitter: @orcabio.


Corporate Communications

Kelsey Grossman


Investor Relations

Joshua Murray